Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Volume: 32, Issue: 9, Pages: 2352 - 2361
Published: Jul 16, 2021
Abstract
Background In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes. Methods In this prespecified analysis of dapagliflozin's effects in patients with stage 4 CKD (eGFR<30 mL/min per 1.73m2) at...
Paper Details
Title
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Published Date
Jul 16, 2021
Volume
32
Issue
9
Pages
2352 - 2361
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History